Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755852 | 1.00 | SLC2A1 (0.54) | SLC2A1KCNH2FAAHACHE | |
| SCHEMBL5755845 | 1.00 | SLC2A1 (0.54) | SLC2A1KCNH2FAAHACHE | |
| SCHEMBL5759487 | 0.87 | SLC2A1 (0.60) | SLC2A1KCNH2 | |
| SCHEMBL5758574 | 0.87 | SLC2A1 (0.60) | SLC2A1KCNH2 | |
| SCHEMBL5759496 | 0.87 | SLC2A1 (0.60) | SLC2A1KCNH2 | |
| SCHEMBL4281144 | 0.86 | SLC2A1 (0.51) | SLC2A1KCNH2 | |
| SCHEMBL4281150 | 0.86 | SLC2A1 (0.51) | SLC2A1KCNH2 | |
| SCHEMBL4281155 | 0.86 | SLC2A1 (0.51) | SLC2A1KCNH2 | |
| SCHEMBL5753152 | 0.85 | SLC2A1 (0.53) | SLC2A1KCNH2 | |
| SCHEMBL5757572 | 0.83 | SLC2A1 (0.52) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343765-B1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20040077656-A1 | Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1343765-A1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050040-A1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERAZINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077656-A1 | Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents | NQO2, ASNS, QARS1 | SLC2A1 3955/4885KCNH2 1467/4885FAAH 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.